Navigation Links
Arno Therapeutics Reports 2008 Year-End Financial Results
Date:3/31/2009

PARSIPPANY, N.J., March 31 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced its financial results for the year ended December 31, 2008.

For the year ended December 31, 2008, Arno reported a net loss of $12.9 million, or $0.81 per share, compared to a net loss of $3.4 million, or $0.34 per share, for the year ended 2007. Total operating expenses for the year ended December 31, 2008 were $12.1 million, an increase of $8.8 million compared to the year ended 2007. Included in operating expenses for the years ended December 31, 2008 and 2007 were non-cash stock-based compensation expenses of $1.1 million and $0.1 million, respectively. The increase in operating expenses in 2008 was primarily attributed to clinical and pre-clinical development expenses of our three drug candidates, merger related fees and increased headcount.

Total research and development expenses for the year ended December 31, 2008 were $9.8 million, compared to $2.9 million in 2007. Research and development expenses for the years ended 2008 and 2007 included non-cash stock-based compensation expenses of $0.5 million and $0.1 million, respectively. The increase in research and development expenses of $6.9 million for the year ended 2008 compared to 2007 was primarily attributed to clinical development costs associated with AR-67, our lead clinical development compound which has completed Phase I enrollment, in addition to the in-licensing and pre-clinical development costs associated with our other two drug candidates AR-12 and AR-42, which we in-licensed in 2008.

General and administrative expenses for the year ended 2008 were $2.3 million compared to $0.4 million for the year ended 2007. General and administrative expenses for the years ended 2008 and 2007 included non-cash stock-based compensation expenses of $0.7
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
2. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
3. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
4. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
5. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
6. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
7. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
8. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
9. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
10. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... 2015 Cambridge Semantics , ... by Semantic Web technology, and Informa , ... services for the academic and scientific, professional and ... solution ‘Smart Data Lake for Clinical Trial and ... 2015 Bio-IT ‘Best of Show’ Award. , ...
(Date:4/16/2015)... April 16, 2015 Regis Technologies looks ... Association for Cancer Research (AACR) annual meeting. Regis will ... Center, starting Saturday, April 18, in Philadelphia and running ... to title of the oldest and largest organization focused ... and grants, and partners with survivors to promote awareness ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... , LONDON, Sept. 8 ... services to pharmaceutical and biotechnology companies, is pleased to announce ... office. Walter Colasante, as a Vice President, and Sophie ... and reimbursement expertise and expand its current offerings. , ...
... Sept. 8 PDL BioPharma, Inc. (PDL) (Nasdaq: ... ended September 30, 2009 of approximately $71 million, as compared ... revenues are based on second quarter product sales by PDL,s ... by MedImmune. When compared with 2008, royalty revenue for foreign ...
... PAREXEL International Corporation (Nasdaq: PRXL ) announced today it ... Boston, MA. Josef von Rickenbach, Chairman and Chief Executive Officer, ... EDT on Friday, September 11, 2009. , , ... "Upcoming Events" section on PAREXEL,s "Investors" homepage at www.PAREXEL.com ...
Cached Biology Technology:PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of the Lawson Health Research Institute and Professor of ... of Medicine & Dentistry at The University of Western ... biology from rebro University in Sweden. Dr. ... and the only recipient this year in the field ...
... of a seething, breathing microbial world. Microorganisms populate every ... of the human skin, to rainforest floors, to hydrothermal ... powerful and pervasive role of microbes in sustaining life, ... is the subject of The Uncharted Microbial World: Microbes ...
... twins are not genetically identical. This surprising finding ... a study being published today in the prestigious journal ... be of great significance for research on hereditary diseases ... How can it be that one identical twin might ...
Cached Biology News:Unexplored microbes hold incredible potential for science and industry 2Unexplored microbes hold incredible potential for science and industry 3
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
In plasmid or lambda vector. Please inquire for more details!...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: